Shree Ganesh Remedies Ltd

- The transcript from the Q2FY25 earnings call of Shree Ganesh Remedies Limited does not mention any current or planned fundraising through debt or equity. - No specific comments were made about raising capital for ongoing or future projects. - Capex plans for expansion (blocks 9, 10, 11 at Ankleshwar and new blocks at Dahej) are contingent on project approvals and customer contracts but no financing details were discussed. - The company is focusing on phased project developments, backed by existing resources and project-specific investments rather than broad fundraising. - Management emphasizes organic growth and capacity expansion based on customer demand without indicating external equity or debt issuance.

- Blocks 9, 10, and 11 at Ankleshwar will be commissioned and designed only when specific projects or chemistry requirements arise; typical Capex per block ranges between ₹10-20 crore, totaling ₹50-80 crore for the three blocks. - Block 7 at Dahej is being finalized; construction usually takes 15-18 months post-approval. - Dahej site is planned for large-scale, dedicated customer projects with major Capex starting 1.5 to 2 years from now after signing supply contracts. - Current capacity expansions at Ankleshwar and ongoing efforts aim to support scale-up and sample submissions before major Dahej investments. - The company employs a project-driven Capex approach, building capacity aligned with customer demand and technology. - Block 8 has started commercial operations from Q1 FY25 and is expected to contribute meaningfully soon. - Innovation efforts include backward integration and technology improvements to maintain margins and production efficiency.

- Revenue growth is expected driven by increasing CRAMS (Contract Research and Manufacturing Services) projects, with trial quantities being supplied and ramp-up over multiple quarters. - Peak volumes for CRAMS projects are anticipated 1.5 to 2 years down the line, indicating gradual scale-up. - New blocks (9,10,11) at Ankleshwar planned but will be commissioned based on confirmed projects; gross block addition estimated at Rs. 50-80 crores. - Dahej site expansion is planned for commercial-scale production once supply contracts are signed; construction expected to take 15-18 months after groundwork. - European market demand has been dampened recently but expected to stabilize with increased inquiries from multiple geographies including Europe, Japan, and USA. - Specialty chemicals and fine chemicals segments are showing promise with new inquiries and potential supplier upgrades. - Long-term projects indicate stable revenue streams 2-3 years ahead. - Overall margin guidance is 24-28% EBITDA, with higher margins in early CRAMS phases balancing out over time.

- Growth expected to continue driven by strategic focus on product mix optimization and profitability enhancement (Page 4). - Commercial supply for CRAMS projects ramping up over multiple quarters; peak volumes expected 1.5 to 2 years down the line (Pages 13-15). - New blocks (9, 10, 11) and Dahej site expansions planned, contingent on project contracts, indicating capacity for future scale (Pages 13-14). - EBITDA margins anticipated to normalize in the 24-28% range over the medium term; peak margin of 30%+ seen recently considered aberration due to initial CRAMS projects (Page 11). - Revenue contribution from CRAMS projects expected to increase gradually but cautiously disclosed due to competitive reasons (Page 15). - Backward integration efforts aimed at maintaining healthy margins amid volume-driven pricing pressure (Page 7). - Overall, a steady revenue and margin growth trajectory is anticipated over 3-5 years with ongoing project commercialization and capacity expansion.

- Currently engaged in multiple CRAMS projects with some commercialized, including one started in Q4 of last year. - Trial quantities for ongoing CRAMS projects expected around Q2 of next financial year. - Major revenue and volume ramp-up from these projects anticipated 1.5 to 2 years down the line. - Customer is conducting market studies to clarify peak volume; clearer visibility expected by Q4 FY25. - Additional CRAMS projects are in pipeline, with sample approvals and R&D ongoing. - No specific orderbook numbers disclosed due to competitive reasons and NDAs. - Blocks 9, 10, and 11 expansions planned post-project confirmation; gross block investment estimated between Rs. 50-80 crores. - Dahej site expansion contingent upon signed supply contracts for high-volume projects; commercial production expected after 1.5-2 years of sample approvals and construction.